Inherited thrombocytopenias correspond to a group of hereditary disorders characterized by a reduced platelet count, platelet dysfunction, and a family history of thrombocytopenia. It is commonly associated with mucocutaneous bleeding. Thrombocytopenia results from mutations in genes involved in megakaryocyte differentiation, platelet formation, and clearance. Here we report on a patient presenting with severe syndromic inherited thrombocytopenia manifesting as spontaneous mucocutaneous bleeds, requiring frequent platelet transfusions. Thrombocytopenia was explained by the presence of 4 mutations in 3 hematopoietic transcription factor genes: FLI1, RUNX1, and ETV6. The patient was successfully treated with high-dose eltrombopag at 150 mg/day, an orally available non-peptide thrombopoietin receptor agonist. Since the start of treatment 23 months ago, the manifestations of bleeding have resolved, and no platelet transfusions or corticosteroids have been required. The patient has no clinical or laboratory evidence of myeloid malignancy so far.

1.
Noris
P
,
Pecci
A
.
Hereditary thrombocytopenias: a growing list of disorders
.
Hematology (Am Soc Hematol Educ Program)
.
2017
Dec
;
2017
(
1
):
385
99
.
[PubMed]
1520-4391
2.
Almazni
I
,
Stapley
R
,
Morgan
NV
.
Inherited Thrombocytopenia: Update on Genes and Genetic Variants Which may be Associated With Bleeding
.
Front Cardiovasc Med
.
2019
Jun
;
6
:
80
.
[PubMed]
2297-055X
3.
Nurden
AT
,
Nurden
P
.
High-throughput sequencing for rapid diagnosis of inherited platelet disorders: a case for a European consensus
.
Haematologica
.
2018
Jan
;
103
(
1
):
6
8
.
[PubMed]
0390-6078
4.
Lambert
MP
.
Inherited Platelet Disorders: A Modern Approach to Evaluation and Treatment
.
Hematol Oncol Clin North Am
.
2019
Jun
;
33
(
3
):
471
87
.
[PubMed]
0889-8588
5.
Songdej
N
,
Rao
AK
.
Hematopoietic transcription factor mutations: important players in inherited platelet defects
.
Blood
.
2017
May
;
129
(
21
):
2873
81
.
[PubMed]
0006-4971
6.
Balduini
CL
,
Savoia
A
,
Seri
M
.
Inherited thrombocytopenias frequently diagnosed in adults
.
J Thromb Haemost
.
2013
Jun
;
11
(
6
):
1006
19
.
[PubMed]
1538-7933
7.
Zaninetti
C
,
Gresele
P
,
Bertomoro
A
,
Klersy
C
,
De Candia
E
,
Veneri
D
,
Barozzi
S
,
Fierro
T
,
Alberelli
MA
,
Musella
V
,
Noris
P
,
Fabris
F
,
Balduini
CL
,
Pecci
A
.
Eltrombopag for the treatment of inherited thrombocytopenias: a phase 2 clinical trial.
Haematologica.2019 Jul 4. pii: haematol.
2019
.223966.doi: .[Epub ahead of print].
8.
Favier
R
,
Jondeau
K
,
Boutard
P
,
Grossfeld
P
,
Reinert
P
,
Jones
C
, et al
Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases
.
Thromb Haemost
.
2003
Nov
;
90
(
5
):
893
7
.
[PubMed]
0340-6245
9.
Di Paola
J
,Porter CC.ETV6-Related Thrombocytopenia and Leukemia Predisposition. Blood.
2019
Jun
27
.pii: blood.2019852418.doi: .[Epub ahead of print].
10.
Sinawat
S
,
Kitkhuandee
A
,
Auvichayapat
N
,
Auvichayapat
P
,
Yospaiboon
Y
,
Sinawat
S
.
Hypoimmunoglobulinemia and protein C deficiency in a girl with Jacobsen syndrome: a case report
.
J Med Assoc Thai
.
2013
Jul
;
96
(
7
):
870
3
.
[PubMed]
0125-2208
11.
Pinto da Costa
N
,
Armari-Alla
C
,
Plantaz
D
,
Pagnier
A
.
[Bernard-Soulier syndrome revealed by major neonatal thrombocytopenia]
.
Arch Pediatr
.
2003
Nov
;
10
(
11
):
983
5
.
[PubMed]
0929-693X
12.
Beck
MN
,
Kuchler
H
,
Roulet
M
,
Beck
D
.
Prolonged remission induced by cyclosporine in a patient with familial thrombocytopenia and enteropathy
.
Pediatr Hematol Oncol
.
1995
May-Jun
;
12
(
3
):
289
93
.
[PubMed]
0888-0018
13.
McLeod
AG
,
Pai
M
,
Carter
RF
,
Squire
J
,
Barr
RD
.
Familial Evans syndrome: a report of an affected sibship
.
J Pediatr Hematol Oncol
.
1999
May-Jun
;
21
(
3
):
244
7
.
[PubMed]
1077-4114
14.
Fattizzo
B
,
Levati
G
,
Cassin
R
,
Barcellini
W
.
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation
.
Drugs
.
2019
Aug
;
79
(
12
):
1305
19
.
[PubMed]
0012-6667
15.
Pecci
A
,
Gresele
P
,
Klersy
C
,
Savoia
A
,
Noris
P
,
Fierro
T
, et al
Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations
.
Blood
.
2010
Dec
;
116
(
26
):
5832
7
.
[PubMed]
0006-4971
16.
Gabelli
M
,
Marzollo
A
,
Notarangelo
LD
,
Basso
G
,
Putti
MC
.
Eltrombopag use in a patient with Wiskott-Aldrich syndrome
.
Pediatr Blood Cancer
.
2017
Dec
;
64
(
12
):
e26692
.
[PubMed]
1545-5009
17.
Prica
A
,
Sholzberg
M
,
Buckstein
R
.
Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials
.
Br J Haematol
.
2014
Dec
;
167
(
5
):
626
38
.
[PubMed]
0007-1048
18.
Fenaux
P
,
Muus
P
,
Kantarjian
H
,
Lyons
RM
,
Larson
RA
,
Sekeres
MA
, et al
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy
.
Br J Haematol
.
2017
Sep
;
178
(
6
):
906
13
.
[PubMed]
0007-1048
19.
Giagounidis
A
,
Mufti
GJ
,
Fenaux
P
,
Sekeres
MA
,
Szer
J
,
Platzbecker
U
, et al
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia
.
Cancer
.
2014
Jun
;
120
(
12
):
1838
46
.
[PubMed]
0008-543X
20.
Mittelman
M
,
Platzbecker
U
,
Afanasyev
B
,
Grosicki
S
,
Wong
RS
,
Anagnostopoulos
A
, et al
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
.
Lancet Haematol
.
2018
Jan
;
5
(
1
):
e34
43
.
[PubMed]
2352-3026
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.